‘Catalytic’ doses of fructose may benefit glycaemic control without harming cardiometabolic risk factors: a small meta-analysis of randomised controlled feeding trials
Contrary to concerns that fructose may have adverse metabolic effects, there is evidence that small, ‘catalytic’ doses ( ≤ 10 g/meal) of fructose decrease the glycaemic response to high-glycaemic index meals in human subjects. To assess the longer-term effects of ‘catalytic’ doses of fructose, we un...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Cambridge University Press
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411192/ |
| id |
pubmed-3411192 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-34111922012-08-03 ‘Catalytic’ doses of fructose may benefit glycaemic control without harming cardiometabolic risk factors: a small meta-analysis of randomised controlled feeding trials Sievenpiper, John L. Chiavaroli, Laura de Souza, Russell J. Mirrahimi, Arash Cozma, Adrian I. Ha, Vanessa Wang, D. David Yu, Matthew E. Carleton, Amanda J. Beyene, Joseph Di Buono, Marco Jenkins, Alexandra L. Leiter, Lawrence A. Wolever, Thomas M. S. Kendall, Cyril W. C. Jenkins, David J. A. Systematic Review with Meta-analysis Contrary to concerns that fructose may have adverse metabolic effects, there is evidence that small, ‘catalytic’ doses ( ≤ 10 g/meal) of fructose decrease the glycaemic response to high-glycaemic index meals in human subjects. To assess the longer-term effects of ‘catalytic’ doses of fructose, we undertook a meta-analysis of controlled feeding trials. We searched MEDLINE, EMBASE, CINAHL and the Cochrane Library. Analyses included all controlled feeding trials ≥ 7 d featuring ‘catalytic’ fructose doses ( ≤ 36 g/d) in isoenergetic exchange for other carbohydrates. Data were pooled by the generic inverse variance method using random-effects models and expressed as mean differences (MD) with 95 % CI. Heterogeneity was assessed by the Q statistic and quantified by I2. The Heyland Methodological Quality Score assessed study quality. A total of six feeding trials (n 118) met the eligibility criteria. ‘Catalytic’ doses of fructose significantly reduced HbA1c (MD − 0·40, 95 % CI − 0·72, − 0·08) and fasting glucose (MD − 0·25, 95 % CI − 0·44, − 0·07). This benefit was seen in the absence of adverse effects on fasting insulin, body weight, TAG or uric acid. Subgroup and sensitivity analyses showed evidence of effect modification under certain conditions. The small number of trials and their relatively short duration limit the strength of the conclusions. In conclusion, this small meta-analysis shows that ‘catalytic’ fructose doses ( ≤ 36 g/d) may improve glycaemic control without adverse effects on body weight, TAG, insulin and uric acid. There is a need for larger, longer ( ≥ 6 months) trials using ‘catalytic’ fructose to confirm these results. Cambridge University Press 2012-08-14 2012-02-21 /pmc/articles/PMC3411192/ /pubmed/22354959 http://dx.doi.org/10.1017/S000711451200013X Text en Copyright © The Authors 2012. The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercial-ShareAlike licence <http://creativecommons.org/licenses/by-nc-sa/2.5/>. The written permission of Cambridge University Press must be obtained for commercial re-use. http://creativecommons.org/licenses/by-nc-sa/2.5/ The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercial-ShareAlike licence <http://creativecommons.org/licenses/by-nc-sa/2.5/>. (http://creativecommons.org/licenses/by-nc-sa/2.5/>) The written permission of Cambridge University Press must be obtained for commercial re-use. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Sievenpiper, John L. Chiavaroli, Laura de Souza, Russell J. Mirrahimi, Arash Cozma, Adrian I. Ha, Vanessa Wang, D. David Yu, Matthew E. Carleton, Amanda J. Beyene, Joseph Di Buono, Marco Jenkins, Alexandra L. Leiter, Lawrence A. Wolever, Thomas M. S. Kendall, Cyril W. C. Jenkins, David J. A. |
| spellingShingle |
Sievenpiper, John L. Chiavaroli, Laura de Souza, Russell J. Mirrahimi, Arash Cozma, Adrian I. Ha, Vanessa Wang, D. David Yu, Matthew E. Carleton, Amanda J. Beyene, Joseph Di Buono, Marco Jenkins, Alexandra L. Leiter, Lawrence A. Wolever, Thomas M. S. Kendall, Cyril W. C. Jenkins, David J. A. ‘Catalytic’ doses of fructose may benefit glycaemic control without harming cardiometabolic risk factors: a small meta-analysis of randomised controlled feeding trials |
| author_facet |
Sievenpiper, John L. Chiavaroli, Laura de Souza, Russell J. Mirrahimi, Arash Cozma, Adrian I. Ha, Vanessa Wang, D. David Yu, Matthew E. Carleton, Amanda J. Beyene, Joseph Di Buono, Marco Jenkins, Alexandra L. Leiter, Lawrence A. Wolever, Thomas M. S. Kendall, Cyril W. C. Jenkins, David J. A. |
| author_sort |
Sievenpiper, John L. |
| title |
‘Catalytic’ doses of fructose may benefit glycaemic control without harming cardiometabolic risk factors: a small meta-analysis of randomised controlled feeding trials |
| title_short |
‘Catalytic’ doses of fructose may benefit glycaemic control without harming cardiometabolic risk factors: a small meta-analysis of randomised controlled feeding trials |
| title_full |
‘Catalytic’ doses of fructose may benefit glycaemic control without harming cardiometabolic risk factors: a small meta-analysis of randomised controlled feeding trials |
| title_fullStr |
‘Catalytic’ doses of fructose may benefit glycaemic control without harming cardiometabolic risk factors: a small meta-analysis of randomised controlled feeding trials |
| title_full_unstemmed |
‘Catalytic’ doses of fructose may benefit glycaemic control without harming cardiometabolic risk factors: a small meta-analysis of randomised controlled feeding trials |
| title_sort |
‘catalytic’ doses of fructose may benefit glycaemic control without harming cardiometabolic risk factors: a small meta-analysis of randomised controlled feeding trials |
| description |
Contrary to concerns that fructose may have adverse metabolic effects, there is evidence that small, ‘catalytic’ doses ( ≤ 10 g/meal) of fructose decrease the glycaemic response to high-glycaemic index meals in human subjects. To assess the longer-term effects of ‘catalytic’ doses of fructose, we undertook a meta-analysis of controlled feeding trials. We searched MEDLINE, EMBASE, CINAHL and the Cochrane Library. Analyses included all controlled feeding trials ≥ 7 d featuring ‘catalytic’ fructose doses ( ≤ 36 g/d) in isoenergetic exchange for other carbohydrates. Data were pooled by the generic inverse variance method using random-effects models and expressed as mean differences (MD) with 95 % CI. Heterogeneity was assessed by the Q statistic and quantified by I2. The Heyland Methodological Quality Score assessed study quality. A total of six feeding trials (n 118) met the eligibility criteria. ‘Catalytic’ doses of fructose significantly reduced HbA1c (MD − 0·40, 95 % CI − 0·72, − 0·08) and fasting glucose (MD − 0·25, 95 % CI − 0·44, − 0·07). This benefit was seen in the absence of adverse effects on fasting insulin, body weight, TAG or uric acid. Subgroup and sensitivity analyses showed evidence of effect modification under certain conditions. The small number of trials and their relatively short duration limit the strength of the conclusions. In conclusion, this small meta-analysis shows that ‘catalytic’ fructose doses ( ≤ 36 g/d) may improve glycaemic control without adverse effects on body weight, TAG, insulin and uric acid. There is a need for larger, longer ( ≥ 6 months) trials using ‘catalytic’ fructose to confirm these results. |
| publisher |
Cambridge University Press |
| publishDate |
2012 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411192/ |
| _version_ |
1611547391270322176 |